Abstract
Serum 3α-androstanediol glucuronide (3α-diol G) measurements may indicate the extent of androgen metabolism and action in target tissues. To test this supposition we measured serum 3α-diol G concentrations in 23 women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including 13 with the salt-losing and 10 with the simple virilizing form, while they were receiving glucocorticoid and, in some cases, mineralocorticoid therapy. Their mean age was 28.3 yr (range, 17.9-38.7 yr). Twenty-four-hour urinary 17-ketosteroid excretion, plasma androstenedione and testosterone levels, and serum 3α-diol G levels were measured during the follicular phase. The values were within or below the normal range in 87%, 78%, 70%, and 91% of the patients, respectively. By contrast, plasma 17-hydroxyprogesterone levels were normal in only 12% of the patients. Serum 3α-diol G levels correlated well with 24-h urinary 17-ketosteroid excretion (r = 0.75) and plasma 17-hydroxyprogesterone (r = 0.77), androstenedione (r = 0.84), and testosterone (r = 0.93) levels. The serum 3α-diol G levels were not significantly different in the women with the salt-losing form and those with the simple virilizing form. However, they were significantly lower (P<0.05) in the women with normal menses compared to those with abnormal menses. This finding underscores the validity of serum 3α-diol G measurements as indicators of androgen production and metabolism in women. The excellent correlation between the serum 3α-diol G levels and standard measures of control indicates that the former measurement may be a useful adjunct in the management of women with congenital adrenal hyperplasia.
| Original language | English |
|---|---|
| Pages (from-to) | 105-109 |
| Number of pages | 5 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 69 |
| Issue number | 1 |
| State | Published - Jan 1 1989 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
Serum 3α-androstanediol glucuronide measurements in sexually mature women with congenital adrenal hyperplasia during therapy. / Reiner, B. J.; Donohoue, P. A.; Migeon, C. J.; Berkovitz, Gary.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 69, No. 1, 01.01.1989, p. 105-109.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum 3α-androstanediol glucuronide measurements in sexually mature women with congenital adrenal hyperplasia during therapy
AU - Reiner, B. J.
AU - Donohoue, P. A.
AU - Migeon, C. J.
AU - Berkovitz, Gary
PY - 1989/1/1
Y1 - 1989/1/1
N2 - Serum 3α-androstanediol glucuronide (3α-diol G) measurements may indicate the extent of androgen metabolism and action in target tissues. To test this supposition we measured serum 3α-diol G concentrations in 23 women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including 13 with the salt-losing and 10 with the simple virilizing form, while they were receiving glucocorticoid and, in some cases, mineralocorticoid therapy. Their mean age was 28.3 yr (range, 17.9-38.7 yr). Twenty-four-hour urinary 17-ketosteroid excretion, plasma androstenedione and testosterone levels, and serum 3α-diol G levels were measured during the follicular phase. The values were within or below the normal range in 87%, 78%, 70%, and 91% of the patients, respectively. By contrast, plasma 17-hydroxyprogesterone levels were normal in only 12% of the patients. Serum 3α-diol G levels correlated well with 24-h urinary 17-ketosteroid excretion (r = 0.75) and plasma 17-hydroxyprogesterone (r = 0.77), androstenedione (r = 0.84), and testosterone (r = 0.93) levels. The serum 3α-diol G levels were not significantly different in the women with the salt-losing form and those with the simple virilizing form. However, they were significantly lower (P<0.05) in the women with normal menses compared to those with abnormal menses. This finding underscores the validity of serum 3α-diol G measurements as indicators of androgen production and metabolism in women. The excellent correlation between the serum 3α-diol G levels and standard measures of control indicates that the former measurement may be a useful adjunct in the management of women with congenital adrenal hyperplasia.
AB - Serum 3α-androstanediol glucuronide (3α-diol G) measurements may indicate the extent of androgen metabolism and action in target tissues. To test this supposition we measured serum 3α-diol G concentrations in 23 women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including 13 with the salt-losing and 10 with the simple virilizing form, while they were receiving glucocorticoid and, in some cases, mineralocorticoid therapy. Their mean age was 28.3 yr (range, 17.9-38.7 yr). Twenty-four-hour urinary 17-ketosteroid excretion, plasma androstenedione and testosterone levels, and serum 3α-diol G levels were measured during the follicular phase. The values were within or below the normal range in 87%, 78%, 70%, and 91% of the patients, respectively. By contrast, plasma 17-hydroxyprogesterone levels were normal in only 12% of the patients. Serum 3α-diol G levels correlated well with 24-h urinary 17-ketosteroid excretion (r = 0.75) and plasma 17-hydroxyprogesterone (r = 0.77), androstenedione (r = 0.84), and testosterone (r = 0.93) levels. The serum 3α-diol G levels were not significantly different in the women with the salt-losing form and those with the simple virilizing form. However, they were significantly lower (P<0.05) in the women with normal menses compared to those with abnormal menses. This finding underscores the validity of serum 3α-diol G measurements as indicators of androgen production and metabolism in women. The excellent correlation between the serum 3α-diol G levels and standard measures of control indicates that the former measurement may be a useful adjunct in the management of women with congenital adrenal hyperplasia.
UR - http://www.scopus.com/inward/record.url?scp=0024403761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024403761&partnerID=8YFLogxK
M3 - Article
C2 - 2732292
AN - SCOPUS:0024403761
VL - 69
SP - 105
EP - 109
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 1
ER -